Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28264696 | 0.84 | PLG (0.40) | NCF1LMNAPLGPLATCNR1 | |
| SCHEMBL19201203 | 0.80 | NCF1 (0.39) | NCF1LMNAPLGPLATALDH1A1 | |
| SCHEMBL19201201 | 0.80 | NCF1 (0.39) | NCF1CNR1ALDH1A1CNR2KDM4E | |
| Hydrochloric Acid SCHEMBL19183246 | 0.79 | CYP3A4 (0.38) | NCF1CNR1ALDH1A1CNR2POLB | |
| Hydrochloric Acid SCHEMBL21570515 | 0.79 | NCF1 (0.38) | NCF1LMNAPLGPLATALDH1A1 | |
| SCHEMBL16977567 | 0.79 | NCF1 (0.52) | NCF1LMNAALDH1A1KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL17711696 | 0.77 | NCF1 (0.50) | NCF1LMNAALDH1A1KDM4EPOLB | |
| SCHEMBL4637449 | 0.77 | CA1 (0.42) | LMNACNR1ALDH1A1KDM4EPOLB | |
| SCHEMBL31336838 | 0.75 | NCF1 (0.46) | NCF1LMNAPLGPLATALDH1A1 | |
| SCHEMBL4634095 | 0.74 | NCF1 (0.50) | NCF1LMNAPLGPLATALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230523-A | Benzimidazole derivatives as modulators of ROR-gamma | 生命医药有限责任公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-109071509-B | Benzimidazole derivatives as modulators of ROR-gamma | 生命医药有限责任公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| CN-109071509-A | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | 生命医药公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3408268-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | NCF1 2580/4885LMNA 4216/4885PLG 4643/4885 |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | RORB, RORC, RORA | NCF1 2040/4885LMNA 4449/4885PLG 4548/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | NCF1 1436/4885LMNA 4554/4885PLG 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.